Innovative PRiME Report Launched
An innovative plan has been developed by the Local Enterprise Partnership (LEP), the North West Coast Academic Health Science Network (NWC AHSN) and Liverpool Health Partners (LHP) to enable the Liverpool City Region (LCR) to become the fastest place in the UK to develop and commercialise quality research in precision medicine.
And with Liverpool Health Partners (LHP) as lead delivery partner, a report entitled Liverpool Precision in Medicine (PRiME) has now been published with LHP Executive Director, Professor Sir Munir Pirmohamed describing it as a "coherent, deliverable action plan until 2020 that identifies LCR's assets in precision medicine.”
Liverpool City Region is already at the heart of the Government's Health North initiative with the aim of unlocking the potential of the north through partnership with life sciences minister George Freeman.
Sir Munir Pirmohamed continued: "Liverpool City Region itself serves a population of more than half a million and includes some of the highest levels of deprivation and poverty cross the country. Some of our mortality rates are 76% higher than the European average. Liverpool City Region is also commonly referred to as the cancer capital of Europe so we believe this plan will be widely welcomed."
Also, welcoming the report Robert Hough, Chair, Liverpool City Region Local Enterprise Partnership (LEP) said: “The PRiME report is a further example of how Liverpool City Region is putting science and innovation right at the heart of the Northern Powerhouse and establishing itself as a global leader in the Life Science and Health sector.
“By identifying the City Region’s assets in precision medicine, we will be able to build on our strengths in this area, tapping into our regional expertise that will not only bring national and local benefits, but act as a magnet for inward investment. This initiative therefore creates significant follow-through momentum.”
Within the wider north-west region, NWC AHSN has been appointed as the national lead for personalised medicine. Liverpool City Region is already home to excellent genomics facilities that have underpinned significant R&D, providing the city region with a competitive advantage in precision medicine. Dr. Liz Mear, Chief Executive NWC AHSN, added: “The AHSN has sponsored this report because our role is drive forward improvements in health care; precision medicine is the key to predicting and preventing disease and targeting treatments so they are bespoke to individual patients. This is an exciting change in how we provide health care and we will be working on ways to speed up the introduction of personalised medicine and bring about real benefits for the population.”
Sir Ian Gilmore, LHP Chairman added: “PRiME also provides a shared vision, set of priorities and action plan for the purposes of commercialising research in precision medicine, driving associated economic benefits and positive health outcomes. It is in effect, the precursor for further detailed study and facilitation of work around precision medicine but critically will contribute to the delivery of the LCR innovation plan."
Jo Pisani, partner with Price Warerhouse Coopers who led the work on PRiME and who runs the company’s UK Pharma & Life Sciences consulting practice said: “Liverpool PRiME represents the front line of cross-sector collaboration between life sciences, pharma, the NHS, Local Enterprise Partnerships, industry and government. We look forward to continuing to bring our skills, experience and thought leadership to this pioneering agenda, and are proud to have played a role in such an exciting and leading-edge programme."
The successful bid for the North West Coast NHS Genomic Medicine Centre (NWC GMC), a partnership led by Liverpool Women’s Hospital alongside the North West Coast Academic Health Science Network, Liverpool Health Partners and involving several other NHS Trust from the region, has further strengthened genomics in the region.
Angela Douglas, Programme lead for the NWC GMC said: “We have a vision and an aspiration for Liverpool to be a prime provider of NHS Genomic Services beyond the 100,000 Genome Project; we want to build on the strong foundation of the GMC, create genomic pathways enabling an NHS transformation legacy that will accelerate uptake with advanced genomic medicine practice, integrated into the NHS, delivering better outcomes for our patients. The NW Coast GMC, as of 11th September, is one of only two GMCs that have exceeded their trajectory forecast for patient recruitment and has been at the top of this GMC performance leader board, for recruiting patients into the project, since the ‘Go Live’ date in May 2015 . The PriME report will be fundamental to realising those aspirations.”
The plan has already received strong support from amongst others, Sir Alasdair Breckenridge (Former Chairman MHRA) stated:
"Precision medicine implies giving the appropriate drug in the appropriate dose at the appropriate time to the appropriate patient. This concept has gained great traction with the emergence of genomic medicine and represents one of the most important advances for the treatment of an increasing number of common diseases. As scientific knowledge increases, so will the scope of precision medicine."
He added: "Liverpool City Region is extremely well placed to make important advances in the field of precision medicine. This has already been recognised by major funders of medical scientific research in the UK-the Wellcome Trust, the MRC and the Department of Health, all of whom have invested heavily in academic medicine in Liverpool City Region. In addition, the NHS in the city region has learned how to work harmoniously with academia in this field, a partnership which is crucial for success. I am extremely pleased to be involved in this important development and I give it my strongest support."
Four priorities have been identified which will drive the ambitious vision of Liverpool PRiME. Along with a focus on industry engagement and strategic communication, they critically include the Liverpool Biomedical Research Centre and the FUTURE initiative which aims to create a database of 3000 healthy volunteers who will be fully genotyped for drug disposition genes that will provide a unique resource that will facilitate early phase studies for Industry and healthcare.
For copies of the PRiME Executive Summary please contact firstname.lastname@example.org and email@example.com
1, LHP is a strategic partnership of ten primary and secondary care NHS organisations and two Higher Education Institutions (University of Liverpool and Liverpool School of Tropical Medicine) working together to deliver excellence in research, education and service optimisation across Cheshire and Merseyside. LHP also works with regional networks including the NWC AHSN and NWC CLAHRC.
With access to world-class facilities and clinical and scientific expertise, LHP is in a unique position to develop medical research breakthroughs and translate them into direct clinical benefits for patients.
2, The North West Coast AHSN covers the areas of Cheshire, Merseyside, South Cumbria and Lancashire, serving a population of approximately four million residents. The Network is a product of the Government’s Innovation, Health and Wealth strategy and is one of 15 established across England. Its primary role is to bring together NHS organisations, universities and businesses to ensure that health and social care innovation is spread at “scale and pace” with consequent benefits for the health and wealth of individuals, communities, regions and the nation.
3, Liverpool City Region’s Local Enterprise Partnership is the primary economic development company in the region, and the most innovative of its kind in the country, driving forward greatly accelerated economic growth across key sectors with the potential to create thousands of new jobs in the next decade. LEP income includes funds from the European Regional Development Fund (ERDF).
The core activities of the LCRLEP include:
1. Strategic Economic Development
2. Business Growth
3. Key Growth Sectors
For further information visit www.liverpoollep.org
ERDF in the Northwest: The European Regional Development Fund (ERDF) is making a real difference to people and businesses in the North West. With €755 million to invest between 2007 and 2013, ERDF is enhancing the competitiveness of the region’s economy by supporting growth in enterprise and employment. ERDF in the North West is managed by the Department for Communities and Local Government. For further information visit www.communities.
4. The University of Liverpool is one of the UK’s leading research institutions with an annual turnover of £435 million, including £114 million for research. Liverpool is ranked in the top 1% of higher education institutions worldwide and is a member of the Russell Group. Visit www.liv.ac.uk or follow us on twitter at: http://www.twitter.com/livuninews
5. Liverpool Women’s NHS Foundation Trust specialises in the health of women and their babies - both within the hospital and out in the community. Collectively our team represents some of the most outstanding expertise and experience in this field. Our maternity team cares for women and their babies from conception to birth supported by our neonatal team who provide around the clock care for premature and new born babies needing specialist care. Our renowned fertility team helps families to improve the chance of conceiving babies. In gynaecology, we take care of women with the many varied conditions associated with the female reproductive system and are a renowned centre for gynaecology oncology and our genetics team supports families with the diagnosis and counselling of genetic conditions.
Clinical research is a major part of the Trust’s work. It means we can continually improve the healthcare we provide to our patients and develop new and improved treatments and medications. Also as a teaching hospital, we work closely with the University of Liverpool to deliver the highest standards of undergraduate and post-graduate medical education and training.